Neurology

Real World Evidence Solutions Market worth $10.83 billion by 2030 with 14.8% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 19, 2025 /PRNewswire/ -- The global Real World Evidence Solutions Market, valued at US$4.74 billion in 2024,…

4 months ago

Ryght AI Partners with Global CRO Biorasi to Deliver AI-Powered Feasibility Solutions to Biotech and Biopharma Sponsors

Advanced AI Platform Enables More Accurate Site Selection and Faster Study Startup Across Key Therapeutic Areas Partnership brings real-time site…

4 months ago

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company")…

4 months ago

Hemostemix’s Expands its Marketing Team Focused on Sales in Florida

Calgary, Alberta--(Newsfile Corp. - August 14, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous stem cell…

4 months ago

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its…

4 months ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company…

4 months ago

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the…

4 months ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations CNSide® may…

4 months ago

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on…

4 months ago

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on…

4 months ago